Getting Under the Skin: Updates in the Treatment of Pediatric Atopic Dermatitis
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Click Here to Manage Email Alerts
Overview
Release date: February 28, 2024
Expiration date: February 28, 2025
Estimated time to complete activity: 60 minutes
PROVIDER STATEMENT
This CME activity for ACCME credit is provided by Integrity CE, LLC.
This CE activity for AANP credit is jointly provided by Global Education Group and Integrity CE, LLC.
DISCLOSURE OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
PROGRAM OVERVIEW
Uncontrolled atopic dermatitis (AD) can have dire, lifelong consequences for children and their families. However, medical science has developed several treatments that target the molecular drivers of this immuno-inflammatory skin disease that has negative effects on overall health and quality of life. Join AD expert Dr. Peter Lio for this on-demand video activity about systemic therapeutic options for infants, children, and adolescents who are affected by moderate-to-severe AD.
TARGET AUDIENCE
This educational activity has been designed to meet the needs of pediatric dermatologists, dermatologists, pediatricians, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage pediatric patients with atopic dermatitis.
LEARNING OBJECTIVES
Upon completion of this educational activity, participants should be able to:
- Characterize the extracutaneous consequences of uncontrolled moderate-to-severe AD on patients and parents/caregivers
- Delineate the immuno-inflammatory molecular catalysts that underly moderate-to-severe manifestations of pediatric AD
- Describe how to integrate systemic therapeutic options for infants, children, and adolescents who are affected by moderate-to-severe AD
FACULTY
Peter Lio, MD, FAAD
Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Founding Partner, Medical Dermatology Associates of Chicago
Chicago, Illinois
DISCLOSURE OF CONFLICTS OF INTEREST
Integrity CE, LLC and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Peter Lio, MD, FAAD
Advisory Boards: AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Boston Skin Science (KPAway), Burt’s Bees, Castle Biosciences, Concerto Biosciences, Dermavant, Dermira, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosciences, Kimberly-Clark, LEO, Level Ex, Lipidor AB, L'Oréal, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, SkinFix, Theraplex, Unilever, Verrica, YobeeCare
Patent Holder: Theraplex AIM (patent pending)
Research: AbbVie, AOBiome, Regeneron/Sanofi Genzyme
Speaker: AbbVie, Eli Lilly, Galderma, Incyte, LEO, L'Oréal, Pfizer, Regeneron/Sanofi Genzyme
Stock Options: Altus Labs, Boston Skin Science (KPAway), Concerto Biosciences, LearnSkin,
Micreos, YobeeCare
The Integrity CE, LLC and Global Education Group planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
DIRECTIONS TO LEARNER
There are no fees for participating and receiving CME credit for this activity. During the period of February 28, 2024 through February 28, 2025, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 67% or better and a completed activity evaluation form.
ACCREDITATION
Physician Continuing Education
ACCREDITATION STATEMENT
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION
Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity CE, LLC. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour (which includes 0.0 hour(s) of pharmacology).
CONTACT INFORMATION
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.
For information about AANP approval of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC and Global Education Group do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
MEDIA
Internet
MINIMUM SYSTEM REQUIREMENTS
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
• Adobe® Flash® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus
For optimal performance, the use of Internet Explorer below 8 is not recommended
DISCLAIMER
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.